These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38451831)

  • 1. Concurrent NRAS-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
    Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsy for
    Güttlein L; Luca MR; Esteso F; Fresno C; Mariani J; Otero Pizarro M; Brest E; Starapoli S; Kreimberg K; Teves P; Mendoza Bertelli A; R Girotti M; Salanova R; O'Connor JM
    Future Oncol; 2022 Sep; 18(29):3277-3287. PubMed ID: 36004810
    [No Abstract]   [Full Text] [Related]  

  • 4. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
    Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
    Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
    BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
    Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
    BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate detection of KRAS, NRAS and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR.
    Nagakubo Y; Hirotsu Y; Amemiya K; Oyama T; Mochizuki H; Omata M
    BMC Med Genomics; 2019 Nov; 12(1):162. PubMed ID: 31711486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
    Modest DP; Ricard I; Heinemann V; Hegewisch-Becker S; Schmiegel W; Porschen R; Stintzing S; Graeven U; Arnold D; von Weikersthal LF; Giessen-Jung C; Stahler A; Schmoll HJ; Jung A; Kirchner T; Tannapfel A; Reinacher-Schick A
    Ann Oncol; 2016 Sep; 27(9):1746-53. PubMed ID: 27358379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.
    Negru S; Papadopoulou E; Apessos A; Stanculeanu DL; Ciuleanu E; Volovat C; Croitoru A; Kakolyris S; Aravantinos G; Ziras N; Athanasiadis E; Touroutoglou N; Pavlidis N; Kalofonos HP; Nasioulas G
    BMJ Open; 2014 May; 4(5):e004652. PubMed ID: 24859998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study.
    Sanchez-Ibarra HE; Jiang X; Gallegos-Gonzalez EY; Cavazos-González AC; Chen Y; Morcos F; Barrera-Saldaña HA
    PLoS One; 2020; 15(7):e0235490. PubMed ID: 32628708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
    Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
    J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
    Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
    Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
    Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
    BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1
    Mesti T; Rebersek M; Ocvirk J
    Radiol Oncol; 2023 Mar; 57(1):103-110. PubMed ID: 36942906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.